Align Technology, Inc. $ALGN Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. grew its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 286.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 144,189 shares of the medical equipment provider’s stock after purchasing an additional 106,853 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Align Technology were worth $27,299,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Ninety One North America Inc. lifted its position in Align Technology by 46.5% during the second quarter. Ninety One North America Inc. now owns 139,133 shares of the medical equipment provider’s stock valued at $26,342,000 after buying an additional 44,135 shares in the last quarter. Truist Financial Corp increased its stake in shares of Align Technology by 2.3% in the second quarter. Truist Financial Corp now owns 4,227 shares of the medical equipment provider’s stock worth $800,000 after buying an additional 95 shares during the last quarter. Signaturefd LLC increased its stake in shares of Align Technology by 17.1% in the second quarter. Signaturefd LLC now owns 961 shares of the medical equipment provider’s stock worth $182,000 after buying an additional 140 shares during the last quarter. Patton Fund Management Inc. bought a new stake in shares of Align Technology in the second quarter worth $227,000. Finally, Bank Pictet & Cie Europe AG bought a new stake in Align Technology during the second quarter valued at $930,000. 88.43% of the stock is owned by institutional investors and hedge funds.

Align Technology Price Performance

Shares of ALGN stock opened at $132.17 on Friday. The stock has a market cap of $9.58 billion, a P/E ratio of 22.29, a price-to-earnings-growth ratio of 1.45 and a beta of 1.70. Align Technology, Inc. has a one year low of $122.00 and a one year high of $246.19. The stock has a fifty day moving average price of $140.20 and a 200 day moving average price of $165.72.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.06 billion. Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The firm’s revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.41 earnings per share. Align Technology has set its Q3 2025 guidance at EPS. Equities research analysts anticipate that Align Technology, Inc. will post 7.98 EPS for the current year.

Align Technology declared that its Board of Directors has initiated a stock buyback plan on Tuesday, August 5th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other news, CEO Joseph M. Hogan acquired 7,576 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was purchased at an average cost of $131.49 per share, for a total transaction of $996,168.24. Following the completion of the transaction, the chief executive officer directly owned 184,945 shares in the company, valued at $24,318,418.05. This trade represents a 4.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.66% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Mizuho set a $210.00 price target on shares of Align Technology in a report on Thursday, July 31st. Evercore ISI upped their price objective on shares of Align Technology from $200.00 to $220.00 and gave the stock an “outperform” rating in a report on Wednesday, July 9th. Wells Fargo & Company dropped their price target on shares of Align Technology from $246.00 to $199.00 and set an “overweight” rating on the stock in a research report on Thursday, July 31st. Zacks Research raised shares of Align Technology from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Finally, Stifel Nicolaus reduced their price objective on shares of Align Technology from $275.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.00.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.